Search

Displaying results 1311 - 1320 of 10000 in total
  1. Drug

    DTS-201

    go.drugbank.com/drugs/DB06071
    Experimental

    DTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for the treatment of various solid tumors. It is activated in the tumor environment. … DTS-201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and potentially other tumors which are not currently treated with doxorubicin but which

  2. Drug

    Medazepam

    go.drugbank.com/drugs/DB13437
    Investigational

    Mixtures: TRANKO-BUSKAS 10 MG + 10 MG KAPLI TABLET, 20 ADET, TRANKO-BUSKAS 10 MG + 10 MG KAPLI TABLET, 40 ADETProducts: NOBRAL 10 MG KAPSÜL, 20 ADET, NOBRAL 10 MG KAPSÜL, 250 ADET
  3. Drug

    Varenicline

    go.drugbank.com/drugs/DB01273
    ApprovedInvestigational

    Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015. … In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors. On March 9, 2015, the U.S.

    Mixtures: CHAMPIX 0,5 MG 1 MG FILM KAPLI TABLET, 11 VE 14 ADET, CHAMPIX 0,5 MG 1 MG FILM KAPLI TABLET, 11 VE 14 ADETCategories: Drugs Used in Addictive Disorders, Drugs Used in Nicotine Dependence
  4. Drug

    Captopril

    go.drugbank.com/drugs/DB01197
    ApprovedInvestigational

    Captopril may be used in the treatment of hypertension.

    Mixtures: CAPOZIDE 50/25 MG TABLETAS, CAPTOPRIL E IDROCLOROTIAZIDE HEXALCategories: Agents Acting on the Renin-Angiotensin System
  5. Drug

    Agalsidase alfa

    go.drugbank.com/drugs/DB15874
    ApprovedInvestigational

    [A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009. … [A220343] Agalsidase alfa was granted EMA approval on 3 August 2001.[L16413]

    Products: REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML
  6. Drug

    Lanreotide

    go.drugbank.com/drugs/DB06791
    ApprovedInvestigational

    It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007. … Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome

    Products: Mytolac 60 mg Injektionslösung in einer Fertigspritze, Mytolac 90 mg Injektionslösung in einer Fertigspritze
  7. Drug

    Beroctocog alfa

    go.drugbank.com/drugs/DB14473
    ApprovedInvestigational

    Mixtures: ALPHANATE FOR INJECTION 250 iu/vial, ALPHANATE FOR INJECTION 500 iu/vialProducts: KOATE-DVI 250 IU/5 ML IV ENJEKSİYON İÇİN LİYOFİLZE TOZ İÇEREN FLAKON, KOATE-DVI 500 IU/5 ML IV ENJEKSİYON İÇİN LİYOFİLZE TOZ İÇEREN FLAKON
  8. Drug

    Isatuximab

    go.drugbank.com/drugs/DB14811
    ApprovedInvestigational

    granted Orphan Drug designation and approved on March 2nd, 2020, for the treatment of multiple myeloma. … [L12099] It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma.

    Products: SARCLİSA 100 MG/5 ML IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADET, SARCLİSA 500 MG/25 ML IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADET
  9. Drug

    Satralizumab

    go.drugbank.com/drugs/DB15762
    ApprovedInvestigational

    [eculizumab] in June 2019 and [inebilizumab] in June 2020). … Satralizumab was first approved for use in Canada in June 2020 for the treatment of AQP4 antibody-positive patients with NMOSD.

    Products: ENSPRYNG 120 mg/1ml solution for injection in pre-filled syringe, ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1ML
  10. Drug

    Quinagolide

    go.drugbank.com/drugs/DB09097
    ApprovedWithdrawn

    Quinagolide is currently available in several countries including Canada, but not approved for treatment in the United States. … These drugs are effective in patients who are intolerant or resistant to [DB01200].

    Synonyms: (+-)-N,N-Diethyl-N'-((3R*,4aR*,10aS*)-1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo(g)quinolin-3-yl)sulfamideProducts: Norprolac 0,025 mg u. 0,050 mg - Tabletten (Startpackung), NORPROLAC® 0.025 MG